Ultragenyx Pharmaceutical Inc.
Symbol: RARE
NASDAQ
43.01
USDDzisiejsza cena rynkowa
-5.9104
Wskaźnik P/E
0.0654
Wskaźnik PEG
3.54B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Ultragenyx Pharmaceutical Inc. (RARE) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 2271.64 | 777.1 | 896.7 | 999.1 | |||||||||||||
balance-sheet.row.short-term-investments | 1482.9 | 363.6 | 614.8 | 432.6 | |||||||||||||
balance-sheet.row.net-receivables | 323.63 | 73.4 | 40.4 | 28.4 | |||||||||||||
balance-sheet.row.inventory | 129.93 | 34 | 26.8 | 16.2 | |||||||||||||
balance-sheet.row.other-current-assets | -638.48 | -777.1 | 68.9 | -187.2 | |||||||||||||
balance-sheet.row.total-current-assets | 2554.45 | 732.2 | 883.9 | 856.6 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 1207.13 | 290.6 | 285.7 | 176.2 | |||||||||||||
balance-sheet.row.goodwill | 177.62 | 44.4 | 44.4 | 44.4 | |||||||||||||
balance-sheet.row.intangible-assets | 646.86 | 166.3 | 160.1 | 130.8 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 824.48 | 210.7 | 204.5 | 175.2 | |||||||||||||
balance-sheet.row.long-term-investments | 436.17 | 199.9 | 154.5 | 293.9 | |||||||||||||
balance-sheet.row.tax-assets | 80.98 | 6 | 6.1 | 8.9 | |||||||||||||
balance-sheet.row.other-non-current-assets | 244.34 | 51.7 | 10.7 | 11.6 | |||||||||||||
balance-sheet.row.total-non-current-assets | 2793.09 | 758.8 | 661.5 | 665.8 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.account-payables | 158.56 | 42.1 | 43.3 | 17.1 | |||||||||||||
balance-sheet.row.short-term-debt | 91.02 | 12.6 | 11.8 | 11.1 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 928.7 | 30.6 | 19.8 | 30.9 | |||||||||||||
Deferred Revenue Non Current | 1736.75 | 862.3 | 0 | 1.5 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 123.45 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 410.65 | 29.2 | 204.7 | 145.6 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3746.75 | 935.2 | 931.7 | 418.5 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 108.94 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.total-liab | 4771.12 | 1215.6 | 1193 | 599.8 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.31 | 0.1 | 0.1 | 0.1 | |||||||||||||
balance-sheet.row.retained-earnings | -13315.3 | -3387.7 | -2781 | -2073.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -1.79 | 0.6 | -6.6 | -1.4 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 13893.21 | 3662.3 | 3140 | 2997.5 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 5347.54 | 1491 | 1545.4 | 1522.4 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | 576.42 | 275.4 | 352.5 | 922.6 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 5347.54 | - | - | - | |||||||||||||
Total Investments | 1852.69 | 563.5 | 620.3 | 726.5 | |||||||||||||
balance-sheet.row.total-debt | 1013.14 | 43.2 | 31.6 | 42 | |||||||||||||
balance-sheet.row.net-debt | 506.37 | -170.4 | -101.4 | -265.6 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -613.35 | -606.6 | -707.4 | -454 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 29.61 | 26 | 18.2 | 13.2 | |||||||||||||
cash-flows.row.deferred-income-tax | -143.91 | -1.6 | -1.6 | 48.7 | |||||||||||||
cash-flows.row.stock-based-compensation | 140.2 | 135.2 | 130.4 | 105 | |||||||||||||
cash-flows.row.change-in-working-capital | -32.76 | -15.1 | 60.2 | -63.2 | |||||||||||||
cash-flows.row.account-receivables | -45.18 | -22.8 | -12.1 | -5.4 | |||||||||||||
cash-flows.row.inventory | -9.2 | -6.9 | -9.7 | -3.1 | |||||||||||||
cash-flows.row.account-payables | -0.41 | 2.4 | 87.4 | 2.8 | |||||||||||||
cash-flows.row.other-working-capital | 22.04 | 12.2 | -5.4 | -57.5 | |||||||||||||
cash-flows.row.other-non-cash-items | 228.72 | -12.7 | 119.8 | 11.7 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -508.67 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | -2.5 | -75 | 0 | |||||||||||||
cash-flows.row.purchases-of-investments | -486.29 | -526.4 | -614.7 | -1012.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 675.52 | 746.2 | 545.1 | 890.9 | |||||||||||||
cash-flows.row.other-investing-activites | -0.66 | -2.5 | -0.8 | -0.9 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 151.13 | 168 | -291.7 | -195.4 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -490.9 | 0 | |||||||||||||
cash-flows.row.common-stock-issued | 354.26 | 379.8 | 10.8 | 78.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | -0.06 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 34.55 | 8.4 | 981.3 | 39.6 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 388.81 | 388.1 | 501.2 | 118.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.43 | 0.5 | -1.1 | -1.2 | |||||||||||||
cash-flows.row.net-change-in-cash | 34.89 | 85.6 | -172 | -416.7 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 524.23 | 219.4 | 137.6 | 309.6 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 489.34 | 133.8 | 309.6 | 726.3 | |||||||||||||
cash-flows.row.operating-cash-flow | -508.67 | -474.8 | -380.5 | -338.7 | |||||||||||||
cash-flows.row.capital-expenditure | -34.94 | -46.8 | -146.1 | -73.1 | |||||||||||||
cash-flows.row.free-cash-flow | -543.61 | -521.6 | -526.6 | -411.8 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 442.59 | 434.2 | 363.3 | 351.4 | |||||||||||||
income-statement-row.row.cost-of-revenue | 59.33 | 45.2 | 28.3 | 16 | |||||||||||||
income-statement-row.row.gross-profit | 383.26 | 389 | 335 | 335.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 652.39 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | 3.63 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.operating-expenses | 963.71 | 958.2 | 983.9 | 717.1 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1023.04 | 1003.5 | 1012.2 | 733.1 | |||||||||||||
income-statement-row.row.interest-income | 29.22 | 26.7 | 11.1 | 1.9 | |||||||||||||
income-statement-row.row.interest-expense | 66.22 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | 3.63 | -0.3 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.total-operating-expenses | -7.69 | -39.3 | -52.8 | -71.2 | |||||||||||||
income-statement-row.row.interest-expense | 66.22 | 66 | 43 | 29.4 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 27.61 | 26 | 9.5 | 0.2 | |||||||||||||
income-statement-row.row.ebitda-caps | -538.27 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -580.45 | -569.2 | -648.9 | -381.7 | |||||||||||||
income-statement-row.row.income-before-tax | -615.22 | -608.5 | -701.7 | -453 | |||||||||||||
income-statement-row.row.income-tax-expense | -1.86 | -1.8 | 5.7 | 1 | |||||||||||||
income-statement-row.row.net-income | -613.35 | -606.6 | -707.4 | -454 |
Często zadawane pytania
Ile wynosi Ultragenyx Pharmaceutical Inc. (RARE) aktywów ogółem?
Ultragenyx Pharmaceutical Inc. (RARE) całkowite aktywa to 1491013000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 236225000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.866.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to -6.450.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to -1.386.
Jaki jest całkowity przychód firmy?
Całkowity przychód to -1.311.
Co to jest Ultragenyx Pharmaceutical Inc. (RARE) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi -606639000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 43169000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 958248000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 118554000.000.